Lily Geidelberg

Lily Geidelberg, PhD, currently serves as a Portfolio Manager and Senior Biotechnology Analyst at Brevan Howard since November 2021. Additionally, Lily has held positions as a Non-Executive Board Member at Versameb AG and eureKING from February 2023 to December 2023 and May 2022 to December 2023, respectively. Previous experience includes a Doctoral Student role at Imperial College London from August 2015 to November 2021, focusing on estimating the impact of interventions on viral epidemics. Lily has also worked as a Consultant Statistician, producing educational materials for the Global Master’s for Public Health, and as a Research Assistant, developing models for HIV intervention impacts. In June to November 2019, Lily functioned as a Policy Advisor for the Department for International Development, providing infectious disease modeling expertise during the Kivu Ebola outbreak. Educational qualifications include a PhD in Mathematical Modelling of Infectious Disease dynamics from Imperial College London, a Master's degree in Evolutionary Biology from the University of Montpellier, and a BA in Natural Sciences from the University of Cambridge.